Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Board of Directors and Corporate Governance
SLNO logo

Soleno Therapeutics Strengthens Governance Framework Ahead of Potential DCCR Drug Submission

SLNO10-KFiling Date: 4/30/2026
Soleno Therapeutics, Inc.
Description

What this story covers

Soleno Therapeutics’ latest filing highlights a robust governance structure, featuring an independent board and performance-linked executive compensation. These measures aim to align leadership with shareholders as the company nears a critical NDA submission for its Prader-Willi Syndrome treatment.

Story snapshot

CompanySoleno Therapeutics, Inc.
TickerSLNO
VariantStandard detailed
Duration12:00
Filing type10-K
PeriodAnnual 2025
IndustryHealthcare & Pharmaceuticals
Accession0001193125-26-197594
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in